Longevity Health Holdings Reports Q1 2026 Financial Results with Net Loss of $1.43 Million

Longevity Health Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.43 million, a slight improvement from a net loss of $1.51 million in the same period last year. The company's gross sales decreased by 21% to $424,390, down from $534,943 in the prior year, while net sales fell by 23% to $391,764. The cost of sales also saw a significant reduction, dropping 36% to $154,739, which contributed to a gross profit of $237,025, compared to $269,823 in the previous year. The overall operating expenses decreased by 12% to $1.57 million, primarily due to reduced research and development costs.

In terms of operational metrics, Longevity Health's cash and cash equivalents stood at $313,396 as of March 31, 2026, a decline from $706,740 at the end of 2025. The company reported a negative working capital of $7.09 million, raising concerns about its liquidity and ability to sustain operations without additional financing. The company’s total liabilities increased to $8.54 million from $8.23 million at the end of the previous fiscal year, reflecting a rise in accounts payable and accrued expenses.

Strategically, Longevity Health completed a private placement on March 16, 2026, raising approximately $200,000 through the sale of 689,656 shares of common stock at $0.29 per share. This capital infusion comes amid a leadership transition, with Janakiram Ajjarapu appointed as the new Chairman and CEO, succeeding Rajiv Shukla, who left the company. The transition is part of a broader effort to stabilize the company and enhance its operational focus.

The company also noted significant changes in its inventory management, with a write-down of $196,684 related to expired raw materials. This adjustment reflects ongoing challenges in managing inventory levels and product expiration, which have been exacerbated by market conditions. The company’s operational focus remains on its core bio-aesthetic products, although it has paused further research and development on its regenerative products.

Looking ahead, Longevity Health Holdings faces substantial uncertainty regarding its ability to continue as a going concern. The company has indicated that it may need to raise additional capital to fund its operations and meet its liabilities. Management is exploring options for financing and potential acquisitions of cash-generating assets, but there are no guarantees that such efforts will be successful. The ongoing geopolitical tensions and economic volatility may further impact the company's financial performance and operational stability.